U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
86413
Substance Class Mixture
Created
by admin
on Sat Dec 16 17:50:15 UTC 2023
Edited
by admin
on Sat Dec 16 17:50:15 UTC 2023
Record UNII
58H6RWO52I
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
Bacitracin
EP   HSDB   INN   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
BACITRACIN [USP IMPURITY]
Common Name English
TOPITRACIN
Common Name English
NSC-755905
Code English
LANABIOTIC COMPONENT BACITRACIN
Common Name English
BACITRACIN [WHO-IP]
Common Name English
PENITRACIN
Common Name English
BACITRACIN [EP MONOGRAPH]
Common Name English
MYCITRACIN COMPONENT BACITRACIN
Common Name English
FORTRACIN
Common Name English
BACITRACIN [JAN]
Common Name English
BACITRACIN [VANDF]
Common Name English
BACIIM
Brand Name English
PARENTRACIN
Common Name English
BACITRACIN [USP MONOGRAPH]
Common Name English
BACIGUENT
Brand Name English
BACI-RX
Brand Name English
BACITRACIN [ORANGE BOOK]
Common Name English
BACILLIQUIN
Common Name English
Bacitracin [WHO-DD]
Common Name English
BACITRACIN [HSDB]
Common Name English
BACITRACINUM [WHO-IP LATIN]
Common Name English
BACITRACIN COMPONENT OF MYCITRACIN
Common Name English
ZUTRACIN
Common Name English
BACITRACIN COMPONENT OF LANABIOTIC
Common Name English
TROPITRACIN
Common Name English
bacitracin [INN]
Common Name English
BACITRACIN(NON-INJECTABLE) [WHO-IP]
Common Name English
BACITRACIN [MI]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 1284
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
WHO-VATC QR02AB04
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
WHO-ATC J01XX10
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
CFR 21 CFR 333.120
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
CFR 21 CFR 524.155
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
WHO-ATC R02AB04
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
CFR 21 CFR 556.70
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
EPA PESTICIDE CODE 6302
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
CFR 21 CFR 333.110
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
CFR 21 CFR 524.154
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
CFR 21 CFR 520.154
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
WHO-ATC D06AX05
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
WHO-VATC QJ01XX10
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
WHO-VATC QD06AX05
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
WHO-VATC QA07AA93
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
Code System Code Type Description
WIKIPEDIA
BACITRACIN
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
PRIMARY
ECHA (EC/EINECS)
215-786-2
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
PRIMARY
NSC
755905
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
PRIMARY
EVMPD
SUB00652MIG
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
PRIMARY
RXCUI
1291
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
PRIMARY RxNorm
WHO INTERNATIONAL PHARMACOPEIA
BACITRACIN
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
PRIMARY Description: A white or pale brownish yellow powder; odourless or with a faint characteristic odour. Solubility: Freely soluble in water, methanol R and ethanol (~750 g/l) TS; practically insoluble in acetone R and ether R. Category: Antiinfective drug. Storage: Bacitracin should be kept in a tightly closed container, protected from light and stored at a temperature between 2? and8?C. If it is intended for parenteral administration, the container should be sterile and sealed so as to exclude micro-organisms. Labelling: The designation sterile Bacitracin indicates that the substance complies with the additional requirements for sterileBacitracin and may be used for parenteral administration or for other sterile applications. Additional information: Bacitracin is hygroscopic. Its solutions deteriorate rapidly at room temperature. Even in the absence oflight, it is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures.
DRUG BANK
DB00626
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
PRIMARY
FDA UNII
58H6RWO52I
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
PRIMARY
NCI_THESAURUS
C295
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
PRIMARY
INN
1167
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
PRIMARY
MERCK INDEX
m2197
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
PRIMARY Merck Index
NDF-RT
N0000008479
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
PRIMARY Decreased Cell Wall Synthesis & Repair [PE]
LACTMED
Bacitracin
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
PRIMARY
DAILYMED
58H6RWO52I
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
PRIMARY
MESH
D001414
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
PRIMARY
CAS
1405-87-4
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
PRIMARY
ChEMBL
CHEMBL1200558
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
PRIMARY
DRUG CENTRAL
281
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
PRIMARY
CHEBI
28669
Created by admin on Sat Dec 16 17:50:16 UTC 2023 , Edited by admin on Sat Dec 16 17:50:16 UTC 2023
PRIMARY
All of the following components must be present:
Structure of BACITRACIN B2
Structure of BACITRACIN B3
Structure of BACITRACIN B1
Structure of BACITRACIN A
Related Record Type Details
STAPHYLOCOCCUS AUREUS
TARGET -> INHIBITOR
MIC
INSULIN-DEGRADING ENZYME
TARGET -> INHIBITOR
BACITRACIN METHYLENEDISALICYLATE SODIUM
SALT/SOLVATE -> PARENT
BACITRACIN, STERILE
SUB_CONCEPT->SUBSTANCE
Related Record Type Details
Structure of BACITRACIN Y
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of BACITRACIN I2
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of BACITRACIN F
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of BACITRACIN H2
IMPURITY -> PARENT
sum of impurities F and G: maximum 2.0 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of BACITRACIN I1
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of BACITRACIN H3
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of BACITRACIN I3
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of BACITRACIN H1
IMPURITY -> PARENT
sum of impurities F and G: maximum 2.0 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Bacitracin
ACTIVE MOIETY
http://apps.who.int/phint/pdf/b/Jb.6.1.40.pdf
Definition References
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966